On August 19, 2019, Aimed Alliance submitted a comment to the Institute for Clinical and Economic Review (ICER) regarding the organization’s comparative effectiveness review of icosapent ethyl and rivoroxaban for cardiovascular disease. Aimed Alliance cautioned against the practice of comparing these two treatments due to their distinct uses and mechanisms of action in the body: icosapent ethyl is a supplement intended for adults to reduce triglyceride levels for adults with severe hypertriglyceridemia while rivaroxaban is a medication used to reduce the risk of stroke and systemic embolism for patients with a nonvalvular atrial defibrillation. The comment also requested that ICER take into further consideration the patient’s perspective as well as incorporating more data from additional relevant studies, and called on ICER to not use the Quality Adjusted Life Years (QALY) metric as a measure for determining comparative effectiveness of treatment.
Last Updated on May 14, 2020 by Aimed Alliance
